Bay City Capital

Investor type Venture Capital
Founders Fred Craves John Diekman

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 132
Average round size
info
The average size of a deal this fund participated in
$25M
Portfolio companies 80
Rounds per year 5.50
Lead investments 15
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.39
Exits 57
Key employees 9
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics
Summary

Bay City Capital appeared to be the VC, which was created in 1997. The venture was found in North America in United States. The main department of described VC is located in the San Francisco.

This organization was formed by Fred Craves, John Diekman. The overall number of key employees were 9.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Pharmion, Hyperion Therapeutics, Merus. The fund has exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical Device, Life Science.

The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Bay City Capital performs on 6 percentage points more the average number of lead investments. When the investment is from Bay City Capital the average startup value is 100-500 millions dollars. The fund is constantly included in 2-6 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2014.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Bay City Capital, startups are often financed by New Leaf Venture Partners, Sofinnova Investments, Canaan Partners. The meaningful sponsors for the fund in investment in the same round are Novo Holdings, Canaan Partners, Alta Partners. In the next rounds fund is usually obtained by New Enterprise Associates, Sofinnova Investments, Alta Partners.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Bay City Capital:
Typical Co-investors
Bay City Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Bay City Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Oculis

Biotechnology
Health Care
Pharmaceutical
$57M04 May 2021 Iceland, Iceland

Bridge Medicines

Pharmaceutical
$10M13 Nov 2020 Sioux Falls, South Dakota, United States

Sembiosys Genetics Inc.

Biotechnology
Genetics
Medical
01 Oct 2020 Calgary, Canada

Xilio Therapeutics

Biotechnology
Health Care
Health Diagnostics
Therapeutics
$100M02 Mar 2020 Massachusetts, United States

Imara

Biopharma
Biotechnology
Collaboration
Genetics
Health Care
Therapeutics
$63M18 Mar 2019 Cambridge, Massachusetts, United States

NextCure

Biopharma
Biotechnology
Health Care
$93M13 Nov 2018 Maryland, United States

Gossamer Bio

Biotechnology
Health Care
Therapeutics
$230M23 Jul 2018 San Diego, California, United States

KBP Biosciences

Biotechnology
Health Care
Pharmaceutical
$76M05 Jan 2018 New Jersey, United States

Oculis

Biotechnology
Health Care
Pharmaceutical
$21M04 Jan 2018 Iceland, Múlaþing

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Bay City Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: